The expansion of the HSV testing market is being fueled by a combination of increasing prevalence of HSV infections, ...

Discover Danaher's strong Q3 results, strategic reinvestments, and biotech growth. See why DHR is poised for future earnings ...

The firm hopes to exploit its first-mover advantage in the OTC space following de novo clearance for an at-home PCR test to detect sexually transmitted infections.

Danaher stock surged over 7% on Tuesday after the company delivered a solid third-quarter performance, with revenues rising 4.5% to $6.1 billion and non-GAAP adjusted EPS of $1.89, significantly ...

The firm's diagnostics revenues rose 4 percent to $2.46 billion, partially due to the growth of respiratory disease testing-related revenues from Cepheid.

Students have the chance to tackle college-level work while they’re still in high school and earn college credit and placement. Testing also offers the opportunity to earn credit for college courses ...